Although some clinical trials have suggested weight reduction after FGF21 analog treatment in subjects with obesity, type 2 diabetes, and fatty liver disease, the evidence for weight loss in subjects with obesity remains inconclusive (23). This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.